Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,otherLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,capitalExpenditures,netBorrowings,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Oct 30, 2017) 4","Short Ratio (Oct 30, 2017) 4","Short % of Float (Oct 30, 2017) 4","Short % of Shares Outstanding (Oct 30, 2017) 4","Shares Short (prior month Sep 28, 2017) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HCYT,-2613810.0,144434000,,,-1407674,-370132,-1407674,1569116,177519,-1403168,-1403168,,-5784,,,,0,376168,1779336,198649,-4506,,-1407674,-1407674,42515999.0,3401832.0,-2613810.0,905860.0,946319.0,136839.0,-45266648.0,29239.0,332310.0,3205300.0,814289.0,333672.0,583408.0,41637.0,62237.0,1149597.0,,89739.0,-1522.0,40051.0,-1308335.0,-1306813.0,11571.0,-40500.0,-1522.0,,,,,-2621892.0,en-US,US,EQUITY,False,Delayed Quote,0.038405,1630519713,0.0048050024,0.0305,0.043,0.0305,66600,USD,PNK,5546988,-14400000,False,False,PRE,4,14.300603,0.0305 - 0.043,us_market,0,H CYTE INC,0.0336,finmb_586895021,Other OTC,"H-CYTE, Inc.",USD,449256,39485,0.032405,5.400833,0.006 - 0.99,-0.951595,-0.9612071,0.006,0.99,0.1,0.04197143,-0.003566429,-0.08497278,0.05666667,-0.018261667,-0.3222647,0.38405,15,America/New_York,EDT,1.38,,,0.99,0.006,0.042,0.0567,449.26k,39.48k,144.43M,,17.65M,67.20%,0.00%,253.31k,5.33,1.40%,1.21%,278.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-381.72%,-335.39%,,1.51M,0.01,-63.00%,1.38M,-5.69M,-5.6M,,,332.31k,0,1.1M,,0.18,0.10,-6.67M,-4.15M,Value,33602,Healthcare,26,"H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.",Tampa,888 664 2983,FL,1609372800,United States,http://www.hcyte.com,86400,201 East Kennedy Boulevard,Biotechnology,Suite 700
t-1,HCYT,-1215816.0,144434000,407.0,,-1560551,-370132,-1560551,1787884,305626,-1494688,-1494688,,-4229,,,,0,464504,1959192,158878,-65863,,-1560551,-1560551,42515999.0,3252007.0,-1215816.0,788961.0,2204168.0,127159.0,-43858974.0,29239.0,1640645.0,2892686.0,674255.0,417727.0,1757202.0,22123.0,202271.0,1006968.0,,-243785.0,1.0,-35122.0,-1796602.0,-1796603.0,12023.0,-3500.0,1.0,3842695.0,-3805488.0,34332.0,,-1135484.0,en-US,US,EQUITY,False,Delayed Quote,0.038405,1630519713,0.0048050024,0.0305,0.043,0.0305,66600,USD,PNK,5546988,-14400000,False,False,PRE,4,14.300603,0.0305 - 0.043,us_market,0,H CYTE INC,0.0336,finmb_586895021,Other OTC,"H-CYTE, Inc.",USD,449256,39485,0.032405,5.400833,0.006 - 0.99,-0.951595,-0.9612071,0.006,0.99,0.1,0.04197143,-0.003566429,-0.08497278,0.05666667,-0.018261667,-0.3222647,0.38405,15,America/New_York,EDT,1.38,,,0.99,0.006,0.042,0.0567,449.26k,39.48k,144.43M,,17.65M,67.20%,0.00%,253.31k,5.33,1.40%,1.21%,278.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-381.72%,-335.39%,,1.51M,0.01,-63.00%,1.38M,-5.69M,-5.6M,,,332.31k,0,1.1M,,0.18,0.10,-6.67M,-4.15M,Value,33602,Healthcare,26,"H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.",Tampa,888 664 2983,FL,1609372800,United States,http://www.hcyte.com,86400,201 East Kennedy Boulevard,Biotechnology,Suite 700
t-2,HCYT,313714.0,144434000,201658.0,,3949879,-370132,3949879,1200254,488640,-943367,-943367,,-1039349,,,,0,649892,1593259,161252,4893246,,3949879,3905573,42489998.0,3621795.0,313714.0,796282.0,4107506.0,122139.0,-42298423.0,25381.0,3437247.0,3025294.0,423283.0,525662.0,3556463.0,4801.0,453243.0,1248132.0,,-182877.0,-2285.0,-109005.0,1607335.0,-1126116.0,30095.0,500.0,-2285.0,3842695.0,-3805488.0,-5967088.0,2735736.0,531169.0,en-US,US,EQUITY,False,Delayed Quote,0.038405,1630519713,0.0048050024,0.0305,0.043,0.0305,66600,USD,PNK,5546988,-14400000,False,False,PRE,4,14.300603,0.0305 - 0.043,us_market,0,H CYTE INC,0.0336,finmb_586895021,Other OTC,"H-CYTE, Inc.",USD,449256,39485,0.032405,5.400833,0.006 - 0.99,-0.951595,-0.9612071,0.006,0.99,0.1,0.04197143,-0.003566429,-0.08497278,0.05666667,-0.018261667,-0.3222647,0.38405,15,America/New_York,EDT,1.38,,,0.99,0.006,0.042,0.0567,449.26k,39.48k,144.43M,,17.65M,67.20%,0.00%,253.31k,5.33,1.40%,1.21%,278.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-381.72%,-335.39%,,1.51M,0.01,-63.00%,1.38M,-5.69M,-5.6M,,,332.31k,0,1.1M,,0.18,0.10,-6.67M,-4.15M,Value,33602,Healthcare,26,"H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.",Tampa,888 664 2983,FL,1609372800,United States,http://www.hcyte.com,86400,201 East Kennedy Boulevard,Biotechnology,Suite 700
t-3,HCYT,-18382980.0,144434000,200000.0,,-6432336,-370132,-6432336,1655280,-50511,-1923035,-1923035,,-363023,,,,0,19500,1942535,70011,-4509301,,-6432336,-6570965,27761076.0,15034617.0,-18382980.0,1237290.0,2683273.0,104246.0,-46248302.0,35054.0,1829912.0,4226852.0,423283.0,669697.0,1978522.0,6891.0,453243.0,1213573.0,10153674.0,-392635.0,-2285.0,-46242.0,1707512.0,-2444265.0,17244.0,11333.0,-2285.0,309082.0,3842695.0,4156656.0,4151777.0,-2248330.0,en-US,US,EQUITY,False,Delayed Quote,0.038405,1630519713,0.0048050024,0.0305,0.043,0.0305,66600,USD,PNK,5546988,-14400000,False,False,PRE,4,14.300603,0.0305 - 0.043,us_market,0,H CYTE INC,0.0336,finmb_586895021,Other OTC,"H-CYTE, Inc.",USD,449256,39485,0.032405,5.400833,0.006 - 0.99,-0.951595,-0.9612071,0.006,0.99,0.1,0.04197143,-0.003566429,-0.08497278,0.05666667,-0.018261667,-0.3222647,0.38405,15,America/New_York,EDT,1.38,,,0.99,0.006,0.042,0.0567,449.26k,39.48k,144.43M,,17.65M,67.20%,0.00%,253.31k,5.33,1.40%,1.21%,278.44k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-381.72%,-335.39%,,1.51M,0.01,-63.00%,1.38M,-5.69M,-5.6M,,,332.31k,0,1.1M,,0.18,0.10,-6.67M,-4.15M,Value,33602,Healthcare,26,"H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute biologics for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.",Tampa,888 664 2983,FL,1609372800,United States,http://www.hcyte.com,86400,201 East Kennedy Boulevard,Biotechnology,Suite 700
